Drug
CTX-009
CTX-009 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
not_yet_recruiting125%
completed250%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
completedphase_2
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
NCT05513742
completedphase_2
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
NCT05506943
not_yet_recruitingphase_1
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
NCT07392957
recruitingphase_1
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
NCT06548412
Clinical Trials (4)
Showing 4 of 4 trials
NCT05513742Phase 2
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
NCT05506943Phase 2
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
NCT07392957Phase 1
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
NCT06548412Phase 1
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4